Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.

The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered by the naturally low affinity of TCR interactions with peptide major histocompatibility complex ligands. Here, we use multimeric forms of soluble heterodimeric alphabeta TCRs for specific detection o...

Full description

Bibliographic Details
Main Authors: Laugel, B, Boulter, J, Lissin, N, Vuidepot, A, Li, Y, Gostick, E, Crotty, L, Douek, D, Hemelaar, J, Price, D, Jakobsen, B, Sewell, A
Format: Journal article
Language:English
Published: 2005
_version_ 1797101777208737792
author Laugel, B
Boulter, J
Lissin, N
Vuidepot, A
Li, Y
Gostick, E
Crotty, L
Douek, D
Hemelaar, J
Price, D
Jakobsen, B
Sewell, A
author_facet Laugel, B
Boulter, J
Lissin, N
Vuidepot, A
Li, Y
Gostick, E
Crotty, L
Douek, D
Hemelaar, J
Price, D
Jakobsen, B
Sewell, A
author_sort Laugel, B
collection OXFORD
description The use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered by the naturally low affinity of TCR interactions with peptide major histocompatibility complex ligands. Here, we use multimeric forms of soluble heterodimeric alphabeta TCRs for specific detection of target cells pulsed with cognate peptide, discrimination of quantitative changes in antigen display at the cell surface, identification of virus-infected cells, inhibition of antigen-specific cytotoxic T lymphocyte activation, and identification of cross-reactive peptides. Notably, the A6 TCR specific for the immunodominant HLA A2-restricted human T cell leukemia virus type 1 Tax(11-19) epitope bound to HLA A2-HuD(87-95) (K(D) 120 microm by surface plasmon resonance), an epitope implicated as a causal antigen in the paraneoplastic neurological degenerative disorder anti-Hu syndrome. A mutant A6 TCR that exhibited dramatically increased affinity for cognate antigen (K(D) 2.5 nm) without enhanced cross-reactivity was generated; this TCR demonstrated potent biological activity even as a monomeric molecule. These data provide insights into TCR repertoire selection and delineate a framework for the selective modification of TCRs in vitro that could enable specific therapeutic intervention in vivo.
first_indexed 2024-03-07T05:56:40Z
format Journal article
id oxford-uuid:eabf4290-c484-4658-9f06-3019ed1a1003
institution University of Oxford
language English
last_indexed 2024-03-07T05:56:40Z
publishDate 2005
record_format dspace
spelling oxford-uuid:eabf4290-c484-4658-9f06-3019ed1a10032022-03-27T11:04:35ZDesign of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:eabf4290-c484-4658-9f06-3019ed1a1003EnglishSymplectic Elements at Oxford2005Laugel, BBoulter, JLissin, NVuidepot, ALi, YGostick, ECrotty, LDouek, DHemelaar, JPrice, DJakobsen, BSewell, AThe use of recombinant T cell receptors (TCRs) to target therapeutic interventions has been hindered by the naturally low affinity of TCR interactions with peptide major histocompatibility complex ligands. Here, we use multimeric forms of soluble heterodimeric alphabeta TCRs for specific detection of target cells pulsed with cognate peptide, discrimination of quantitative changes in antigen display at the cell surface, identification of virus-infected cells, inhibition of antigen-specific cytotoxic T lymphocyte activation, and identification of cross-reactive peptides. Notably, the A6 TCR specific for the immunodominant HLA A2-restricted human T cell leukemia virus type 1 Tax(11-19) epitope bound to HLA A2-HuD(87-95) (K(D) 120 microm by surface plasmon resonance), an epitope implicated as a causal antigen in the paraneoplastic neurological degenerative disorder anti-Hu syndrome. A mutant A6 TCR that exhibited dramatically increased affinity for cognate antigen (K(D) 2.5 nm) without enhanced cross-reactivity was generated; this TCR demonstrated potent biological activity even as a monomeric molecule. These data provide insights into TCR repertoire selection and delineate a framework for the selective modification of TCRs in vitro that could enable specific therapeutic intervention in vivo.
spellingShingle Laugel, B
Boulter, J
Lissin, N
Vuidepot, A
Li, Y
Gostick, E
Crotty, L
Douek, D
Hemelaar, J
Price, D
Jakobsen, B
Sewell, A
Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title_full Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title_fullStr Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title_full_unstemmed Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title_short Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition.
title_sort design of soluble recombinant t cell receptors for antigen targeting and t cell inhibition
work_keys_str_mv AT laugelb designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT boulterj designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT lissinn designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT vuidepota designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT liy designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT gosticke designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT crottyl designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT douekd designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT hemelaarj designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT priced designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT jakobsenb designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition
AT sewella designofsolublerecombinanttcellreceptorsforantigentargetingandtcellinhibition